The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma
Bladder cancer (BC) or carcinoma (BLCA) is predominantly derived from urothelium and includes non-muscle invasive BC (NMIBC) and muscle invasive BC (MIBC). Bacillus Calmette-Guerin (BCG) has long been applied for NMIBC to effectively reduce disease recurrence or progression, whereas immune checkpoin...
Main Authors: | Huiyang Yuan, Yuchen Xiu, Tiantian Liu, Yidong Fan, Dawei Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1126247/full |
Similar Items
-
Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01) -
Mechanism of Genetically-Regulated Response to Bacillus- Calmette Guérin Immunotherapy for Bladder Cancer
by: Hakeem Sam, et al.
Published: (2020-12-01) -
Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01) -
Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
by: Cindy Garcia, et al.
Published: (2016-01-01) -
Intravescical instillation of Calmette-Guérin bacillus and COVID-19 risk
by: Ugo Fedeli, et al.
Published: (2021-02-01)